SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Lakin who started this subject2/8/2001 5:30:04 PM
From: Ian@SI  Read Replies (1) of 1321
 
DJ Newswires coverage of yesterday's release:

Novatis, QLT Inc.: Visudyne Cut Risk Of
Vision Loss

Dow Jones Newswires

ATLANTA -- Novartis AG's (NVS) Novartis Ophthalmics unit and QLT
Inc. (QLTI) said a multi-center Phase III study of Visudyne therapy
showed it reduced the risk of vision loss in patients with wet age-related
macular degeneration.

In a press release Wednesday, Novartis Ophthalmics said the study
included 339 patients at 28 centers throughout North America and Europe
over a period of 24 months.

Visudyne is already approved for the treatment of patients with
predominantly classic subfoveal choroidal neovascularization caused by
age-related macular degeneration, which is the primary cause of severe
vision loss in people over 50 years old.

+++++++++++++++++++

Replay for today's Earnings Conf call available through the QLT website or at 416 626 4100 17726291#

Some nice stuff therein including a survey done during November, at which time
retinal specialists forecasted a 24% increase in patients treated. This call,
leerink asked some intelligent questions designed to allow them to come up
with better earnings estimates / profitability.

They might even acknowledge that QLT is the only game in town for 500,000 people annually who would otherwise go blind over a period of 3-4 years.

Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News